pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

202 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT955Endpoints733BioPharma Dive280BioSpace177Fierce Biotech167onclive165globenewswire health73raps
therapy area
allOncology5570Rare Disease1221Cardiology1040Hematology919Immunology909Vaccines794Pulmonology768Psychiatry & CNS
  • Kailera says obesity pill succeeds in late-stage trial in China
    The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: Compass says depression drug has long-lasting benefits
    Vertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
    Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.
    BioPharma Dive · 1mo ago
← prev
page 4 of 9
next →
59
fda recalls40
fda medwatch29
fda press25
677
Ophthalmology339
Endocrinology & Metabolism335
Pain330
Infectious Disease321
↗ source
  • STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
    Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder
    STAT · 1mo ago↗ source
  • STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms
    Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder, the companies said.
    STAT · 1mo ago↗ source
  • New CDER appointment elevates longtime GLP-1 reviewer
    Acting FDA CDER director Michael Davis has promoted a longtime FDA staffer as an acting deputy director at the drug center. Lisa Yanoff, an agency veteran with expertise in metabolic drug reviews,…
    Endpoints · 1mo ago↗ source
  • Opinion: The smart way to regulate the peptide boom
    “The FDA should pursue a structured, clinician-guided framework” on popular peptides, writes former surgeon general Jerome Adams.
    STAT · 1mo ago↗ source
  • Statins and blood pressure drugs changing health risks of obesity, study suggests
    New research shows obesity patients over 40 are managing blood pressure and cholesterol as well as healthy-weight peers, but younger adults remain at risk.
    STAT · 1mo ago↗ source
  • STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watch
    Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter.
    STAT · 1mo ago↗ source
  • 10 clinical trials to watch in the second half of 2026
    The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
    BioPharma Dive · 1mo ago↗ source
  • Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
    Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.
    BioPharma Dive · 1mo ago↗ source
  • Opinion: I’m an Alzheimer’s specialist. I still missed it in my own father
    “Alzheimer’s is not primarily a disease of old age. It is a decades-long biological process,” writes Elizabeth Bevins.
    STAT · 1mo ago↗ source
  • Diabetes association leader apologizes for expulsion of members, pledges to rebuild trust
    The American Diabetes Association CEO apologizes to five members kicked out of annual convention for distributing protest literature, launches review of what went awry.
    STAT · 2mo ago↗ source
  • Diabetes Association in uproar after members expelled from annual meeting over protest of NIH cuts
    The condemnations keep coming after five diabetes experts were escorted out of an ADA meeting for handing out copies of an editorial criticizing federal research cuts.
    STAT · 2mo ago↗ source
  • When it’s time to save a limb, novel clinic meets unhoused people where they are
    Unmet vascular needs can lead to limb loss among unhoused patients. An unusual Massachusetts General Hospital program meets patients where they are.
    STAT · 2mo ago↗ source
  • Opinion: American horses are obese, too
    “American horses are getting sick in ways that look remarkably familiar,” writes Joshua Moen.
    STAT · 2mo ago↗ source
  • STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA
    You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.
    STAT · 2mo ago↗ source
  • STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending
    You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.
    STAT · 2mo ago↗ source
  • STAT+: Newer GLP-1s, pushback on research cuts, and a protest
    You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.
    STAT · 2mo ago↗ source
  • Senior NIH official pushes MAHA strategy to skeptical ADA audience
    An NIH advisor told researchers gathered at the American Diabetes Association conference that MAHA goals match the agency's priorities.
    STAT · 2mo ago↗ source
  • Male puberty is understudied — but when it starts may predict long-term health risks
    Due to a significant gender gap, far less is known about the health risks of early or late puberty onset among boys than girls.
    STAT · 2mo ago↗ source
  • Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
    Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
    BioPharma Dive · 2mo ago↗ source
  • Servier buys into muscular dystrophy with potentially $2.7B deal
    The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.
    BioPharma Dive · 2mo ago↗ source
  • Opinion: I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’
    Long term, we don’t know what tiny doses of GLP-1s for cosmetic weight loss can do, writes a weight-loss doctor.
    STAT · 2mo ago↗ source
  • Hantavirus risk remains low, CDC says, citing its ‘playbook’ response
    Despite rising concern about the hantavirus outbreak on a cruise ship, two CDC doctors say the risk to the public remains low.
    STAT · 3mo ago↗ source